公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2008 | Radiotherapy in lung adenocarcinoma with brain metastases: Effects of activating epidermal growth factor receptor mutations on clinical response | Gow C.-H.; Chien C.-R.; YIH-LEONG CHANG ; Chiu Y.-H.; SUNG-HSIN KUO ; JIN-YUAN SHIH ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HSIN YANG ; PAN-CHYR YANG | Clinical Cancer Research | 132 | 125 | |
2020 | Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY | Nishio M.; Seto T.; Reck M.; Garon E.B.; Chiu C.-H.; Yoh K.; Imamura F.; Park K.; JIN-YUAN SHIH ; Visseren-Grul C.; Frimodt-Moller B.; Zimmermann A.; Homma G.; Enatsu S.; Nakagawa K.; RELAY Study Investigators | Cancer science | 17 | 12 | |
2019 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial | Nakagawa K.; Garon E.B.; Seto T.; Nishio M.; Ponce Aix S.; Paz-Ares L.; Chiu C.-H.; Park K.; Novello S.; Nadal E.; Imamura F.; Yoh K.; JIN-YUAN SHIH ; Au K.H.; Moro-Sibilot D.; Enatsu S.; Zimmermann A.; Frimodt-Moller B.; Visseren-Grul C.; Reck M.; Chu Q.; Cortot A.; Pujol J.-L.; Fabre E.; Lamour C.; Bischoff H.; Kollmeier J.; Kimmich M.; Engel-Riedel W.; Hammerschmidt S.; Schütte W.; Syrigos K.; Ho J.C.M.; Au K.-H.; Ardizzoni A.; Pasello G.; Gregorc V.; Del Conte A.; Galetta D.; Takahashi T.; Kumagai T.; Hotta K.; Goto Y.; Hosomi Y.; Sakai H.; Takiguchi Y.; Kim Y.H.; Kurata T.; Yamaguchi H.; Daga H.; Okamoto I.; Satouchi M.; Ikeda S.; Kasahara K.; Atagi S.; Azuma K.; Aoe K.; Horio Y.; Yamamoto N.; Tanaka H.; Watanabe S.; Nogami N.; Ozaki T.; Koyama R.; Hirashima T.; Kaneda H.; Tomii K.; Fujita Y.; Seike M.; Nishimura N.; Kato T.; Ichiki M.; Saka H.; Hirano K.; Nakahara Y.; Sugawara S.; Kim S.-W.; Min Y.J.; Lee H.W.; Kang J.-H.; An H.J.; Lee K.H.; Kim J.-S.; Lee G.-W.; Lee S.Y.; Alexandru A.; Udrea A.A.; Juan-Vidal Ó.; Nadal-Alforja E.; Gil-Bazo I.; Ponce-Aix S.; Rubio-Viqueira B.; Alonso Garcia M.; Felip Font E.; Fuentes Pradera J.; Coves Sarto J.; Lin M.-C.; Su W.-C.; Hsia T.-C.; Chang G.-C.; Wei Y.-F.; Su J.; Cicin I.; Goksel T.; Harputluoglu H.; Ozyilkan O.; Henning I.; Popat S.; Hatcher O.; Mileham K.; Acoba J.; Garon E.; Jung G.; Raj M.; Martin W.; Dakhil S. | The Lancet Oncology | 397 | 341 | |
2018 | Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials | Yen C.-J.; Muro K.; Kim T.-W.; Kudo M.; JIN-YUAN SHIH ; Lee K.-W.; Chao Y.; Kim S.-W.; Yamazaki K.; Sohn J.; Cheng R.; Zhang Y.; Binder P.; Mi G.; Orlando M.; Chung H.C. | Journal of Global Oncology | 9 | 0 | |
2015 | Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene | Wu H.; JIN-YUAN SHIH ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 15 | 14 | |
2019 | A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non-small-cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase inhibitor | LUN-CHE CHEN ; JIN-YUAN SHIH ; CHONG-JEN YU ; Yang C.-Y. | Respirology Case Reports | 5 | 4 | |
2017 | Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib | ZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; Chia-Chi Lin ; CHIH-HSIN YANG ; CHONG-JEN YU | Oncologist | 25 | 25 | |
2024 | Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer | JIN-YUAN SHIH ; Luo, Yung-Hung; Chang, Gee-Chen; Chang, John Wen-Cheng; Wang, Chin-Chou; Yang, Tsung-Ying; Fang, Wei-Tse; Shau, Wen-Yi | Journal of the Formosan Medical Association = Taiwan yi zhi | | | |
2017 | Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma | SHENG-KAI LIANG ; MIN-SHU HSIEH ; MENG-RUI LEE ; LI-TA KENG ; JEN-CHUNG KO ; JIN-YUAN SHIH | Oncotarget | 55 | 52 | |
2021 | Real-world insights into patients with advanced NSCLC and MET alterations | Bittoni M.; CHIH-HSIN YANG ; JIN-YUAN SHIH ; Peled N.; Smit E.F.; Camidge D.R.; Arasada R.R.; Oksen D.; Boutmy E.; Stroh C.; Johne A.; Carbone D.P.; Paik P.K. | Lung Cancer | 11 | 9 | |
2022 | Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma | CHIA-LING CHANG ; MIN-SHU HSIEH ; JIN-YUAN SHIH ; Lee, Yi-Hsuan; WEI-YU LIAO ; CHIA-LIN HSU ; CHING-YAO YANG ; KUAN-YU CHEN ; JIH-HSIANG LEE ; CHAO-CHI HO ; TZU-HSIU TSAI ; CHIH-HSIN YANG ; CHONG-JEN YU | Therapeutic advances in medical oncology | 1 | 1 | |
2022 | Recurrence of pericardial effusion after different procedure modalities in patients with non-small-cell lung cancer | Chang L.-K.; YAO-WEN KUO ; SHANG-GIN WU ; KUEI-PIN CHUNG ; JIN-YUAN SHIH | ESMO Open | 2 | 0 | |
2021 | RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non⇓small cell lung cancer | Nakagawa K.; Nadal E.; Garon E.B.; Nishio M.; Seto T.; Yamamoto N.; Park K.; JIN-YUAN SHIH ; Paz-Ares L.; Frimodt-Moller B.; Zimmermann A.H.; Wijayawardana S.; Visseren-Grul C.; Reck M. | Clinical Cancer Research | 28 | 18 | |
2024 | RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants | Nishino, Kazumi; JIN-YUAN SHIH ; Nakagawa, Kazuhiko; Reck, Martin; Garon, Edward B; Carlsen, Michelle; Matsui, Tomoko; Visseren-Grul, Carla; Nadal, Ernest | JTO clinical and research reports | | | |
2022 | RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability | Nadal E.; Horinouchi H.; JIN-YUAN SHIH ; Nakagawa K.; Reck M.; Garon E.B.; Wei Y.-F.; Kollmeier J.; Frimodt-Moller B.; Barrett E.; Lipkovich O.; Visseren-Grul C.; Novello S. | Drug Safety | 6 | 5 | |
2019 | The relevance of docetaxel-related febrile neutropenia to patient-reported symptoms and the quality of life in Japanese, East Asian (Korean, Taiwanese), and Non-east asian patients based on post-hoc analyses of two randomized clinical trials of docetaxel with and without anti-angiogenic agent in advanced non-small cell lung cancer after progression on platinum-based chemotherapy | Omori Y.; Enatsu S.; Brnabic A.J.M.; Rajan N.; JIN-YUAN SHIH ; Kim J.-H.; Park K.; Inoue A. | Japanese Journal of Lung Cancer | 0 | 0 | |
2021 | Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non–small-cell lung cancer: a multicenter study using targeted next-generation sequencing | YEN-TING LIN ; Chiang, Chi-Lu; Hung, Jen-Yu; Lee, Mei-Hsuan; Su, Wu-Chou; Wu, Shang-Yin; Wei, Yu-Feng; Lee, Kang-Yun; Tseng, Yen-Han; Su, Jian; Chung, Hsin-Pei; Lin, Chih-Bin; Ku, Wen-Hui; Chiang, Tsai-Shin; Chiu, Chao-Hua; JIN-YUAN SHIH | European Journal of Cancer | 26 | 21 | |
2018 | Response to Stephane Renaud et al. | WEN-CHI YANG ; JIN-YUAN SHIH ; CHAO-CHI HO ; Feng-Ming Hsu | Radiotherapy and Oncology | 0 | 0 | |
2015 | The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases | YUN CHIANG ; CHIH-HSIN YANG ; Feng-Ming Hsu ; YU-HSUAN CHEN ; JIN-YUAN SHIH ; ZHONG-ZHE LIN ; KENG-HSUEH LAN ; ANN-LII CHENG ; SUNG-HSIN KUO | PLoS ONE | 9 | 9 | |
2022 | Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations | Wang, H-Y; SHANG-GIN WU ; YEN-TING LIN ; CHUNG-YU CHEN ; JIN-YUAN SHIH | ESMO open | 3 | 3 | |